Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$253.3 - $285.89 $4,306 - $4,860
-17 Reduced 1.17%
1,434 $368,000
Q2 2023

Aug 25, 2023

BUY
$275.25 - $318.06 $399,387 - $461,505
1,451 New
1,451 $413,000
Q1 2023

May 15, 2023

SELL
$256.56 - $292.34 $29,247 - $33,326
-114 Reduced 7.72%
1,362 $378,000
Q4 2022

Feb 14, 2023

SELL
$252.44 - $306.72 $23,981 - $29,138
-95 Reduced 6.05%
1,476 $408,000
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $973 - $1,342
-5 Reduced 0.32%
1,571 $418,000
Q2 2022

Aug 12, 2022

BUY
$187.54 - $223.02 $7,689 - $9,143
41 Added 2.67%
1,576 $322,000
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $297,436 - $374,754
1,535 New
1,535 $323,000
Q2 2019

Jul 29, 2019

SELL
$219.29 - $241.72 $9,868 - $10,877
-45 Closed
0 $0
Q4 2018

Jan 22, 2019

BUY
$278.5 - $352.75 $12,532 - $15,873
45 New
45 $14,000

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.4B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Lavaca Capital LLC Portfolio

Follow Lavaca Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lavaca Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lavaca Capital LLC with notifications on news.